Get started

LOW

SPHS Oversold, Filling the Gap, cash/share > share priceSophiris Bio had a Phase III drug trial test showing the drug was not effective and the market overreacted. The chart has a cash/share value (mrq) of $1.74, the float is 16.78 Million Shares (note today's volume alone is a large part of that), so with a tiny float, more cash per share on hand than the market price, and upcoming results for new Phase III results for other products, one can see why people are buying this up right now.
SLong
by trademan1
2
AUDUSD in a very interesting place on long-term graph.Hi traders, Looking the aussie on monthly chart we can see that he is in a very interesting place which is serving (until now) as an area of support. But what don't make very bullish is that we might reach the 0.50% fib (2001 low-2011 high) which also another fib (connecting on 2008 low and 2011 high), 0.618% is there. So looking the daily and we see a close above 8300, then I think a low is in place. Good luck! Thiago Duarte thiago@duarteinvestmentgroup.com @thiagotrader
by dcm2020
Tsla summer predictionAfter that big run, big players cashed in at the top and will want to buy at low prices. I know that there will be resting orders down at 160 level because that was the start of the up move where a fundamental driver was announced. Markets have memories. A double bottom will likely be formed where all the retail traders will buy, maybe off the 200ema, then their stops will be hit, triggering massive sell orders all the way down to 160 where i will be waiting. The way to make money is simply to buy low and sell high! The move down may be in a stair case fashion into the buy level because there will be a lot of interest in this stock. The breakout of the daily trendline provided enough liquidity for the professionals to sell into this weak up move.
NASDAQ:TSLAShort
by EliteTrader101